Merck Receives Warning Letter for Vaccine Operations
The FDA issued a warning letter to Merck and Co. (Whitehouse Station, NJ) on April 28, citing numerous GMP violations at Merck’s vaccine production operations in West Point, PA.
The US Food and Drug Administration (FDA) issued a warning letter to Merck and Co. (Whitehouse Station, NJ) on April 28, citing numerous good manufacturing practice (GMP) violations at Merck’s vaccine production operations in West Point, PA. The FDA also requested a meeting with senior management at Merck to discuss the concerns cited in the warning letter.
Vaccines produced at the facility include the human papillomavirus vaccine Gardasil, and the combination measles, mumps, rubella, and chicken pox vaccine ProQuad.
Specific violations noted on the form include:
- Lack of stability information;
- Over-pressurization of vials;
- Validation procedures on certain machines that were not representative of actual inspection process;
- Failure to quarantine process intermediates associated with filter membranes that caused foaming during filtration, which was associated with leaching into process intermediates.
The FDA has stated that it has no reason to believe the problems affected the safety of Merck’s vaccines. The agency also said that the deficiencies would not affect the availability of the vaccines that are manufactured at the West Point facility, with the exception of PedvaxHIB and COMVAX, which were recalled in December 2007.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
